MorphoSys Chooses Incyte As Its Global Tafasitamab Partner

Analysts Cheer MorphoSys’s Choice Of Commercial Ally And Deal’s Terms

 
• By Sten Stovall

MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.

Partnership
Duo Will Jointly Develop MorphoSys’s CD19 Targeting Antibody • Source: Shutterstock

More from Business

More from Scrip